Inhibition of proliferation and induction of apoptosis in RB116 retinoblastoma cells by afatinib treatment

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
Wei-Jiao ZhanLong-Mei Wang

Abstract

The present study investigates the effect of afatinib on the growth, induction of apoptosis in RB116 cells, and reduction of carcinoma growth in the mice transplanted with RB116 cells. The results from MTT assay revealed that afatinib inhibited the growth of RB116 cells in a dose-dependent manner. Proliferation of RB116 cells was reduced to 64 % on treatment with 200 μM concentration of afatinib after 48 h. Afatinib treatment of RB116 cells at 200 μM concentration induced apoptosis and necrosis in 49.7 and 9.4 %, respectively, after 48 h. In the RB116-transplanted mice, treatment with afatinib at 10-mg/kg doses for 45 days caused a significant (p < 0.005) reduction in the tumor volume compared to the control group. The tissue lysates of the mice containing RB116 transplant showed a significant decrease in the expressions of Ki67 and p53 in the afatinib treatment group after 45 days. However, the expression of caspase-3 was increased and of Bcl-2 remained unaltered on treatment with afatinib. Measurement of the body weight of afatinib-treated animals showed no reduction during the study. Thus, afatinib can be of therapeutic value for the treatment of retinoblastoma.

References

Jun 1, 1987·Ophthalmology·D M Albert
Jan 1, 1994·Mayo Clinic Proceedings·J A Shields, C L Shields
Nov 1, 1995·The British Journal of Dermatology·E HealyJ L Rees
Mar 17, 2001·Nature Reviews. Molecular Cell Biology·Y Yarden, M X Sliwkowski
May 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carlos Rodriguez-GalindoCharles B Pratt
May 28, 2004·International Journal of Clinical Oncology·Takaaki Yanagisawa
Sep 28, 2005·Acta Cirúrgica Brasileira·Suzana Angelica Silva LustosaDelcio Matos
Aug 3, 2007·The Journal of Clinical Investigation·Hongtao ZhangMark I Greene
Jul 28, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kelly M Quesnelle, Jennifer R Grandis
Jan 14, 2012·Expert Opinion on Therapeutic Targets·Parthasarathy SeshacharyuluSurinder K Batra
Aug 22, 2012·Proceedings of the National Academy of Sciences of the United States of America·Heidi GreulichMatthew Meyerson
Nov 17, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Yu-Chieh TsaiJason Chia-Hsien Cheng

❮ Previous
Next ❯

Citations

Nov 25, 2018·Archives of Pharmacal Research·Dong Hyun JoJeong Hun Kim
Feb 13, 2020·Journal of Ophthalmology·Aleksandra Pekacka

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis